A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case –control study

ConclusionsWe have successfully validated our urinary biomarker panel, which was improved by substituting REG1A with REG1B. At a pre-selected cutoff of>80% SN and SP for the affiliated PancRISK score, we demonstrate a clinically applicable risk stratification tool with a binary output for risk of developing PDAC ( ‘elevated’ or ‘normal’). PancRISK provides a step towards precision surveillance for PDAC patients, which we will test in a prospective clinical study, UroPanc.
Source: PLoS Medicine - Category: Internal Medicine Authors: Source Type: research